
-
Glasner says demotion to Conference League would punish 'innocent' Palace
-
New Zealand build big total in 2nd Test against Zimbabwe
-
Trump hosts foes Armenia, Azerbaijan in his latest peace initiative
-
Nigerian scientists await return of Egusi seeds sent to space
-
Pioneer spirit drives Swiss solar-powered plane altitude attempt
-
Thyssenkrupp to spin off marine division amid defence boom
-
Vance and Lammy talk Gaza, fish as US VP starts UK holiday
-
Israel plans to 'take control' of Gaza City, sparking wave of criticism
-
Putin taps key allies ahead of Trump summit, sanctions deadline
-
Two tourists die, fires erupt in Greece amid gale-force winds
-
Lens sign France international Thauvin from Udinese
-
Gold futures hit record on US tariff shock, stocks wobble
-
Man Utd training ground upgrade will foster 'winning culture': Ratcliffe
-
Two tourists die at sea in Greece amid gale-force winds
-
'Optimistic': Champagne growers hope for US tariff shift
-
French firefighters optimistic after controlling vast wildfire
-
Germany suspends arms exports to Israel for use in Gaza
-
Stocks waver, gold futures hit record on US tariff updates
-
Guessand says he jumped at chance to join Aston Villa after sealing move
-
Israel to 'take control' of Gaza City, sparking wave of criticism
-
Accumulating bitcoin a risky digital rush by companies?
-
Liverpool's Slot hints at fresh Isak bid despite 'attacking power'
-
PSG to sign Lille goalkeeper Lucas Chevalier: source
-
Oil industry presence surges at UN plastic talks: NGOs
-
Kipyegon says a woman will run a sub-four minute mile
-
Tokyo soars on trade deal relief as most Asian markets limp into weekend
-
Israel to 'take control' of Gaza City after approving new war plan
-
Australian A-League side Western United stripped of licence
-
'Back home': family who fled front buried after Kyiv strike
-
Indonesia cracks down on pirate protest flag
-
Israeli army will 'take control' of Gaza City: PM's office
-
Australian mushroom murderer accused of poisoning husband
-
Coventry's mettle tested by Russian Olympic debate, say former IOC figures
-
Library user borrows rare Chinese artwork, returns fakes: US officials
-
Parisians hot under the collar over A/C in apartments
-
Crypto group reportedly says it planned sex toy tosses at WNBA games
-
American Shelton tops Khachanov to win first ATP Masters title in Toronto
-
Tokyo soars on trade deal relief as Asian markets limp into weekend
-
New species teem in Cambodia's threatened karst
-
Australian mushroom murderer accused of poisoning husband: police
-
Solid gold, royal missives and Nobel noms: how to win Trump over
-
Canadian teen Mboko outlasts Osaka to win WTA Montreal crown
-
Trump to host Armenia, Azerbaijan for historic 'Peace Signing'
-
Israeli airline's Paris offices daubed with red paint, slogans
-
US raises bounty on Venezuela's Maduro to $50 mn
-
Lebanon cabinet meets again on Hezbollah disarmament
-
France's huge wildfire will burn for days: authorities
-
Bolivia right-wing presidential hopeful vows 'radical change'
-
Trump says would meet Putin without Zelensky sit-down
-
Trump offers data to justify firing of labor stats chief
RBGPF | -5.79% | 71.84 | $ | |
RYCEF | 0.07% | 14.46 | $ | |
CMSC | 0.43% | 23.06 | $ | |
VOD | 1.01% | 11.375 | $ | |
BCC | -0.2% | 83.02 | $ | |
GSK | 0.83% | 37.895 | $ | |
RIO | 1.92% | 61.96 | $ | |
AZN | -0.76% | 73.495 | $ | |
SCS | 0.06% | 16.01 | $ | |
SCU | 0% | 12.72 | $ | |
JRI | -0.04% | 13.405 | $ | |
NGG | -1.04% | 71.335 | $ | |
RELX | -1.76% | 48.21 | $ | |
CMSD | -0.13% | 23.49 | $ | |
BTI | 0.6% | 57.035 | $ | |
BCE | 2.52% | 24.395 | $ | |
BP | 0.06% | 34.21 | $ |

Court to hear lawsuit seeking to ban abortion pill in US
A Texas judge favored by anti-abortion activists will hear arguments Wednesday in an unprecedented challenge to the legality of a widely-used abortion pill.
US District Court Judge Matthew Kacsmaryk announced Monday the hearing on a lawsuit alleging the US Food and Drug Administration (FDA) should never have approved the "dangerous" prescription drug Mifepristone in 2000.
Mifepristone, one component of a two-drug regimen used for medication abortion, has been used by an estimated 5.6 million women to terminate pregnancies since its approval, according to the FDA.
It is can be used in the United States up to 10 weeks of pregnancy.
The pro-abortion rights Guttmacher Institute estimates that more than half of all abortions involve the use of mifepristone.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying its approval "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with using mifepristone.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
Galvanized by the Supreme Court's ruling in June that overturned the constitutional right to an abortion, abortion opponents have now set their sights on obtaining prohibitions on mifepristone.
Already the treatment has been halted in some 15 states which have banned all abortion since the 2022 Supreme Court decision.
The Texas suit seeks to block it nationally by overturning the FDA's approval of the drug.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
Kacsmaryk was targeted by the plaintiffs to hear the case due to his deep conservative Christian beliefs and previous anti-abortion stance.
He had been expected since February 24 to issue a ruling in the case, which asks him to suspend the FDA's approval of the drug while the lawsuit proceeds.
Apparently fearing protestors descending on the courthouse in Amarillo, Texas, Kacsmaryk originally sought to keep the hearing secret until the last minute, but it leaked to media.
If he does order the suspension, it could leave pregnant women with the alternative of using only misoprostol, the second pill in the medication abortion treatment.
But using misoprostol alone is more physically traumatic than the two-pill procedure, and some fear doctors might be unwilling to prescribe it alone.
If mifepristone is banned, "access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
Z.AlNajjar--SF-PST